Search results for: Downs
Sit-downs With Eight All-Stars From OIS XII
PODCAST EPISODE 350 Click here to watch the video version of this podcast. More than 300 clinical thought leaders, pharma industry executives, and ophthalmology investors gathered recently in San Diego, CA, for OIS XII. In addition to announcing pivotal new data, presenters discussed drug and device innovations, advances in clinical trials, and how to gain…
Read MorePeter Downs
Peter Downs has more than 30 years of experience as a business and medical journalist and investigative reporter. He has written for a variety of medical industry publications, including the Medical Business Journal, CBS HealthWatch, and Oncology News International. Prior to joining Market Scope in 2015 and turning his attention to ophthalmology, Peter analyzed markets…
Read MoreOIS XIII Presenting Companies
AgendaSpeakersPresenting CompaniesSponsorsCompanies AttendingVenue OIS XIII PRESENTING COMPANIES Alex Lopez, Chief Commercial Officer – Ace Vision Group Ace Vision Group, Inc, (“AVG” or “the Company”) is an emerging ophthalmic laser device company focused on bringing innovative touchless Eye Laser Therapy to patients suffering from age-related vision loss. The Company is focused on the development and commercialization…
Read MorePresenting Companies OIS Retina 2022
RETINA HOME |AGENDA |SPEAKERS |PRESENTING COMPANIES |SPONSORS |VENUE Jim Taylor, CEO – 2C Tech 2C Tech intends to validate and develop the potential of Nanoparticle technologies to provide effective and meaningful therapeutic benefits to patients with retinal degenerative conditions. Our immediate focus is on the use of Quantum Dots (QDs) as a therapeutic option for…
Read MorePassionate Pursuits With Kiora Pharmaceuticals Brian Strem
PODCAST EPISODE 312 Click here to watch the video version of this podcast. Brian Strem, president and CEO of Kiora Pharmaceuticals, didn’t plan to become an executive, or even an entrepreneur, when he started doing translational research for publicly traded biotech company Cytori Therapeutics. But as his career progressed from the bench to business development…
Read MoreLori-Ann Christie’s Detour to Venture Capital With Visionary Ventures
PODCAST EPISODE 311 Click here to watch the video version of this podcast. A college detour from medical school and into scientific research worked to Lori-Ann Christie’s advantage. Her career has evolved from academic researcher to pharmaceutical industry scientist and director to venture capital fund principal, with each role building on the one before. Christie…
Read MoreThree OIS Podcast Hosts Put the Ophthalmology Innovation Year in Review in Perspective
PODCAST EPISODE 310 Click here to watch the video version of this podcast. The annual tradition of the “Ophthalmology Innovation Year in Review” continues for 2021 with data on National Eye Institute funding, venture deals, public offerings, merger-and-acquisition transactions, Food and Drug Administration approvals, and Phase III trial readouts. In this OIS Podcast,…
Read MoreIndustry Insights on the Glaucoma Market, From OIS Glaucoma Innovation Showcase
PODCAST EPISODE 305
Read MoreSix Oral Retina Drug Development Programs to Watch
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy slows or stops damage that occurs in wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other retinal diseases. Although regular anti-VEGF injections have become the standard of care, they come with notable patient and physician burden. Because of the invasive nature of anti-VEGF therapy, “the majority…
Read MoreOIS Glaucoma Showcase Take-Home: Glaucoma Market Poised For Growth
A growing number of people living past age 60 years, innovation to increase the effectiveness or accessibility of care, and competition are the largest factors driving today’s glaucoma market, said Peter Downs, a writer and analyst with Market Scope at the OIS Glaucoma Innovation Showcase, held virtually. Link to video As for companies driving innovation…
Read MoreChange Creates Opportunity with Ramin Valian
PODCAST EPISODE 303
Read MoreOIS Retina@ASRS Sizes Up the Challenges in Retina Innovation
The first live OIS program in almost two years, OIS Retina@ASRS, was as much an update on what was portrayed as a robust innovation ecosystem directed at the treatment and diagnosis of retinal disease as much as it was about how the space has fared through the COVID-19 pandemic. But it also provided insights into…
Read More